Effective treatment of collecting duct carcinoma in a recipient of a kidney transplant: A case report

Nascimento De Assis,Tabata Carolina Faria; Rapatoni,Liane; Segato,Flavio Nogueira; Pontes,Barbhara Thais Maciel; Muglia,Valdair Francisco; Neto,Miguel Moyses; Romao,Elen Almeida

doi:10.3892/ol.2024.14661

Effective treatment of collecting duct carcinoma in a recipient of a kidney transplant: A case report

Authors:
- Tabata Carolina Faria Nascimento De Assis
- Liane Rapatoni
- Flavio Nogueira Segato
- Barbhara Thais Maciel Pontes
- Valdair Francisco Muglia
- Miguel Moyses Neto
- Elen Almeida Romao
View Affiliations

Affiliations: Division of Nephrology, Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14048‑900, Brazil, Division of Clinical Oncology, Department of Medical Imaging, Haematology and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14048‑900, Brazil, Division of Medical Imaging, Department of Medical Imaging, Haematology and Clinical Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14048‑900, Brazil
Published online on: September 3, 2024 https://doi.org/10.3892/ol.2024.14661
Article Number: 528
Copyright: © Nascimento De Assis et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Collecting duct carcinoma (CDC) is a rare disease associated with a high mortality rate. The present study describes the case of a recipient of a kidney transplant with metastatic allograft CDC whose treatment was successful. The patient underwent nephrectomy, and chemotherapy with gemcitabine and cisplatin, while undergoing haemodialysis treatment and remained in remission after 6 years of follow‑up. There is a lack of information about the treatment and clinical management of CDC; however, the combination of gemcitabine and cisplatin remains as first‑line therapy. The challenge of this case was integrating chemotherapy sessions with dialysis therapy to maintain the effectiveness, tolerability and safety of the oncological treatment. In the present case report, the success of chemotherapy with gemcitabine and cisplatin was demonstrated in a metastatic renal allograft CDC in a patient with end‑stage renal disease, with few side effects and no recurrence of the disease 6 years after the end of treatment.

View Figures

View References

1	Mennitto A, Verzoni E, Peverelli G, Alessi A and Procopio G: Management of metastatic collecting duct carcinoma: An encouraging result in a patient treated with cabozantinib. Clin Genitourin Cancer. 16:e521–e523. 2018. View Article : Google Scholar : PubMed/NCBI
2	Orsola A, Trias I, Raventós CX, Español I, Cecchini L and Orsola I: Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma. Urology. 65:49–54. 2005. View Article : Google Scholar : PubMed/NCBI
3	Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, et al: Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: Results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J Urol. 177:1698–1702. 2007. View Article : Google Scholar : PubMed/NCBI
4	Yin M, Wang W, Rosenberg J, Kaag M, Joshi M, Holder S, Tuanquin L and Drabick JJ: Targeted therapy in collecting duct carcinoma of the kidney: A case report and literature review. Clin Genitourin Cancer. 14:e203–e236. 2016. View Article : Google Scholar : PubMed/NCBI
5	Suarez C, Marmolejo D, Valdivia A, Morales-Barrera R, Gonzalez M, Mateo J, Semidey ME, Lorente D, Trilla E and Carles J: Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease. Front Oncol. 12:9701992022. View Article : Google Scholar : PubMed/NCBI
6	Pepek J, Johnstone P and Jani A: Influence of demographic factors on outcome of collecting duct carcinoma: A surveillance, epidemiology, and end results (SEER) database analysis. Clin Genitourin Cancer. 7:E24–E27. 2009. View Article : Google Scholar : PubMed/NCBI
7	Chapman JR: The KDIGO clinical practice guidelines for the care of kidney transplant recipients. Transplantation. 89:644–645. 2010. View Article : Google Scholar : PubMed/NCBI
8	Truong LD and Shen SS: Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 135:92–109. 2011. View Article : Google Scholar : PubMed/NCBI
9	Carvalho JC, Thomas DG, Mchugh JB, Shah RB and Kunju LP: P63, CK7, PAX8 and INI-1: An optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system. Histopathology. 60:597–608. 2012. View Article : Google Scholar : PubMed/NCBI
10	Rini B, McKiernan J and Chang S: Kidney. Amin M: AJCC Cancer Staging Manual. 8th edition. New York: Springer; pp. pp7392017
11	U.S. Department of Health and Human Services, . Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. November 27–2017.
12	Rimar KJ, Meeks JJ and Kuzel TM: Anti-programmed death receptor 1 blockade induces clinical response in a patient with metastatic collecting duct carcinoma. Clin Genitourin Cancer. 14:e431–e434. 2016. View Article : Google Scholar : PubMed/NCBI
13	Ezaki T, Matsumoto K, Morita S, Shinoda K, Mizuno R, Kikuchi E and Oya M: A case of gemcitabine and cisplatin chemotherapy in a patient with metastatic urothelial carcinoma receiving hemodialysis. Clin Genitourin Cancer. 14:e413–e416. 2016. View Article : Google Scholar : PubMed/NCBI
14	Chang PY, Dai MS, Ho CL and Yao NS: Administration of gemcitabine and cisplatin in cancer patients with renal failure under hemodialysis. J BUON. 18:1058–1061. 2013.PubMed/NCBI
15	Kiani A, Köhne CH, Franz T, Passauer J, Haufe T, Gross P, Ehninger G and Schleyer E: Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: Effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol. 51:266–270. 2003. View Article : Google Scholar : PubMed/NCBI
16	Masumori N, Kunishima Y, Hirobe M, Takeuchi M, Takayanagi A, Tsukamoto T and Itoh T: Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. Jpn J Clin Oncol. 38:182–185. 2008. View Article : Google Scholar : PubMed/NCBI
17	Janus N, Thariat J, Boulanger H, Deray G and Launay-Vacher V: Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 21:1395–403. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zahra MA, Taylor A, Mould G, Coles C, Crawford R and Tan LT: Concurrent weekly cisplatin chemotherapy and radiotherapy in a haemodialysis patient with locally advanced cervix cancer. Clin Oncol. 20:6–11. 2008. View Article : Google Scholar
19	Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, Kitagawa Y, Kuwano H, Nishiyama H, Ishioka C, et al: Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol. 22:210–244. 2018. View Article : Google Scholar : PubMed/NCBI